CN104519879B - 使用类视色素激动剂治疗中性粒细胞减少症的方法 - Google Patents

使用类视色素激动剂治疗中性粒细胞减少症的方法 Download PDF

Info

Publication number
CN104519879B
CN104519879B CN201380041537.6A CN201380041537A CN104519879B CN 104519879 B CN104519879 B CN 104519879B CN 201380041537 A CN201380041537 A CN 201380041537A CN 104519879 B CN104519879 B CN 104519879B
Authority
CN
China
Prior art keywords
day
neutropenia
tamibarotene
composition
neutrophils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380041537.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104519879A (zh
Inventor
L·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Publication of CN104519879A publication Critical patent/CN104519879A/zh
Application granted granted Critical
Publication of CN104519879B publication Critical patent/CN104519879B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201380041537.6A 2012-06-07 2013-06-07 使用类视色素激动剂治疗中性粒细胞减少症的方法 Expired - Fee Related CN104519879B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
US61/656,815 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (2)

Publication Number Publication Date
CN104519879A CN104519879A (zh) 2015-04-15
CN104519879B true CN104519879B (zh) 2018-10-02

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041537.6A Expired - Fee Related CN104519879B (zh) 2012-06-07 2013-06-07 使用类视色素激动剂治疗中性粒细胞减少症的方法

Country Status (13)

Country Link
US (1) US11116738B2 (https=)
EP (1) EP2858636B1 (https=)
JP (1) JP6295249B2 (https=)
KR (1) KR102083046B1 (https=)
CN (1) CN104519879B (https=)
AU (1) AU2013270674B2 (https=)
BR (1) BR112014030279A2 (https=)
CA (1) CA2874850A1 (https=)
ES (1) ES2691493T3 (https=)
MX (1) MX365321B (https=)
NZ (1) NZ702415A (https=)
RU (1) RU2650962C2 (https=)
WO (1) WO2013185105A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
WO2014145295A1 (en) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing aging effects
KR20160113302A (ko) * 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
MX391949B (es) 2015-03-31 2025-03-21 Syros Pharmaceuticals Inc Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
TW201823471A (zh) * 2016-10-06 2018-07-01 美商錫羅斯製藥公司 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
WO2019147187A1 (en) * 2018-01-26 2019-08-01 Agency For Science, Technology And Research Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641091A (zh) * 2007-03-30 2010-02-03 Tmrc株式会社 他米巴罗汀胶囊剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2273288A1 (en) * 1996-12-19 1998-06-25 James Joseph Gibbons Method of treating or inhibiting neutropenia
JP4799803B2 (ja) 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
EP1632241A4 (en) 2003-05-16 2009-07-22 Kyowa Hakko Kirin Co Ltd MEANS FOR THE PREVENTION AND / OR HEALING OF DISEASES IN CONNECTION WITH TISSUE DISORDER
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
JP2008509928A (ja) 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
PT1841432E (pt) 2004-12-02 2010-10-25 Venus Remedies Ltd Composições para combater a resistência aos antibióticos mediada pela beta-lactamase usando inibidores da betalactamase úteis para injecção
WO2006071451A2 (en) 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
DK2026778T3 (en) * 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
US20110052574A1 (en) * 2007-12-06 2011-03-03 Csl Limited Method of inhibition of leukemic stem cells
WO2010028388A1 (en) 2008-09-05 2010-03-11 Solulink Biosciences, Inc. Methods and compositions for direct detection of dna damage
AU2010309388B2 (en) 2009-10-19 2016-03-10 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
JP6242868B2 (ja) 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641091A (zh) * 2007-03-30 2010-02-03 Tmrc株式会社 他米巴罗汀胶囊剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The effects of retinoic Acid analogs on the blast cells of acute myeloblastic-leukemia in culture;Tohda S等;《Int J Oncol.》;19940630;第4卷(第6期);第1311-1314页 *
维甲酸对急性早幼粒细胞白血病白血病细胞诱导分化作用的研究;毕卫真等;《中国医科大学学报》;19911231;第20卷(第2期);第151-155页 *

Also Published As

Publication number Publication date
JP6295249B2 (ja) 2018-03-14
MX2014014930A (es) 2015-07-06
AU2013270674B2 (en) 2017-12-07
JP2015523346A (ja) 2015-08-13
MX365321B (es) 2019-05-29
KR20150035983A (ko) 2015-04-07
CN104519879A (zh) 2015-04-15
NZ702415A (en) 2016-04-29
CA2874850A1 (en) 2013-12-12
US20150164836A1 (en) 2015-06-18
EP2858636B1 (en) 2018-09-05
US11116738B2 (en) 2021-09-14
ES2691493T3 (es) 2018-11-27
RU2650962C2 (ru) 2018-04-18
KR102083046B1 (ko) 2020-02-28
EP2858636A1 (en) 2015-04-15
EP2858636A4 (en) 2016-06-01
RU2014153988A (ru) 2016-07-27
HK1208630A1 (en) 2016-03-11
AU2013270674A1 (en) 2014-12-18
BR112014030279A2 (pt) 2017-09-12
WO2013185105A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
CN104519879B (zh) 使用类视色素激动剂治疗中性粒细胞减少症的方法
CN111787945B (zh) 作为癌症免疫治疗的检查点阻断剂的工程化纳米囊泡
JP6695286B2 (ja) リンパ腫の処置
JP2022172262A (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
EA037117B1 (ru) Новая фармацевтическая композиция, содержащая частицы, содержащие комплекс двухнитевого полирибонуклеотида и полиалкиленимина
EP2978439B1 (en) A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
JP2019503386A (ja) 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
Ahmad et al. Deciphering the enigma of neuron-glial interactions in neurological disorders
CA2155920A1 (en) Use of interferon for the inhibition of proliferation and differentiation of primitive hematopoietic progenitor cells
US20260048083A1 (en) Method of treating alzheimer's disease with expanded natural killer cells
ES2789574T3 (es) Modulación de la activación del inflamasoma de células supresoras derivadas de mieloides para el tratamiento de GvHD o tumor
US20230330193A1 (en) Enhancement of stem cell therapy for cartilage degeneration by anti-oxidant pre-conditioning
CN117159525A (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
HK1208630B (en) Methods for treating neutropenia using retinoid agonists
CN116829142A (zh) 处理和改善癌症的方法
EP4578454A1 (en) Compositions comprising platelet derived extracellular vesicles
WO2025059662A1 (en) Artificial antigen presenting cells to improve t cell function
HK40077184A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
CN118236361A (zh) 牛磺酸联合化疗药物在制备抗肿瘤药物中的应用
HK1215790B (en) A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
HK1226332A1 (en) A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
HK1226332B (en) A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181002